Twin Focus Capital Partners, LLC Immuno Gen, Inc. Transaction History

Twin Focus Capital Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$12.46 - $29.95 $398,720 - $958,400	-32,000 Reduced 50.1%	31,875 $945,000
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $112,500 - $601,500	-30,000 Reduced 31.96%	63,875 $1.21 Million
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $627 - $870	-138 Reduced 0.15%	93,875 $465,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $173 - $316	-55 Reduced 0.06%	94,013 $423,000
Q1 2021 May 12, 2021	SELL	$6.5 - $10.53 $65,000 - $105,300	-10,000 Reduced 9.61%	94,068 $762,000
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $409 - $1,312	193 Added 0.19%	104,068 $355,000
Q4 2019 Feb 13, 2020	SELL	$2.25 - $5.8 $20,245 - $52,188	-8,998 Reduced 7.97%	103,875 $530,000
Q1 2018 May 11, 2018	SELL	$6.7 - $12.95 $2,298 - $4,441	-343 Reduced 0.3%	112,873 $1.19 Million
Q3 2017 Nov 13, 2017	BUY	$5.4 - $8.47 $611,366 - $958,939	113,216	113,216 $866,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Twin Focus Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Twin Focus Capital Partners, LLC with notifications on news.